Allspring Global Investments Holdings LLC Trims Position in Elevance Health, Inc. $ELV

Allspring Global Investments Holdings LLC lessened its stake in Elevance Health, Inc. (NYSE:ELV) by 37.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,724 shares of the company’s stock after selling 7,642 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Elevance Health were worth $4,508,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Physician Wealth Advisors Inc. grew its position in shares of Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after buying an additional 63 shares in the last quarter. Rossby Financial LCC grew its position in shares of Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after buying an additional 44 shares in the last quarter. Activest Wealth Management grew its position in shares of Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after buying an additional 34 shares in the last quarter. Motco grew its position in shares of Elevance Health by 334.8% during the 3rd quarter. Motco now owns 100 shares of the company’s stock worth $32,000 after buying an additional 77 shares in the last quarter. Finally, ORG Partners LLC grew its position in shares of Elevance Health by 120.4% during the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after buying an additional 59 shares in the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: CMS finalized a 2.48% average Medicare Advantage/Part D rate increase for 2027, plus an estimated ~2.5% boost from risk‑adjustment changes (effective ~5% total), directly improving revenue and margin outlook for ELV. Elevance Health Stock Soars After 2.48% Medicare Rate Increase
• Positive Sentiment: Coverage pieces highlight ELV as a clear beneficiary of the stronger‑than‑expected Medicare Advantage rate decision, underpinning near‑term revenue and profitability improvements versus prior street assumptions. 5 Stocks That Should Benefit from the 2026 Medicare Advantage Rate Decision
• Positive Sentiment: Investor commentary and a bullish Seeking Alpha piece call the new Medicare payments a “gift,” arguing ELV’s valuation looks compelling after a significant pullback and technicals suggest a potential bottom. Elevance Health: New Medicare Payment Rate A Gift, And The Chart Looks Good
• Positive Sentiment: BofA upgraded its managed‑care outlook and raised Elevance’s price target, signaling analyst confidence that the policy change and underlying fundamentals support higher valuation. BofA Updates Managed Care Outlook, Raises Elevance Health (ELV) Price Target
• Neutral Sentiment: Deeper analyses unpack how the Medicare rate bump flows through to profit — benefits to revenue are clear but the magnitude depends on membership trends, benefit cost ratios and risk‑adjustment implementation. Medicare Rates Up – What This Really Means For Elevance
• Neutral Sentiment: General market coverage notes health‑insurer peers are rallying on the CMS decision; this is a sector move that benefits ELV but individual execution still matters. Health insurance stocks are soaring on a Medicare update. Here’s what you need to know.
• Neutral Sentiment: Coverage previews and leadership commentary flag a recent executive shuffle focused on government programs; the market will watch whether management changes accelerate government business execution. Will Elevance Health’s (ELV) Leadership Shuffle Refocus Its Core Advantage In Government Programs?
• Negative Sentiment: Other pieces urge caution, noting ELV’s shares have fallen ~27% over the past year and that membership declines, higher benefit expense ratios and conservative guidance still pose risks despite the rate boost. Is It Time To Reassess Elevance Health (ELV) After A 27% One-Year Share Price Slide
• Neutral Sentiment: An earnings preview highlights the items investors should watch in the next report (membership trends, benefit expense and guidance cadence) that will determine whether the positive policy news translates into sustainable EPS upside. Elevance Health earnings preview: What to expect

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Guggenheim cut their target price on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating on the stock in a research report on Thursday, January 29th. Wall Street Zen downgraded shares of Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Robert W. Baird lifted their price objective on shares of Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Royal Bank Of Canada downgraded shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price objective for the company. in a research note on Tuesday, February 3rd. Finally, Wells Fargo & Company reduced their price objective on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a research note on Friday, January 30th. Twelve investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $387.40.

Elevance Health Stock Up 2.8%

NYSE:ELV opened at $311.22 on Wednesday. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $458.75. The stock has a market capitalization of $68.36 billion, a P/E ratio of 12.39, a P/E/G ratio of 1.65 and a beta of 0.49. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54. The company’s 50-day simple moving average is $312.98 and its 200-day simple moving average is $332.28.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. During the same period in the previous year, the company earned $3.84 earnings per share. The business’s revenue for the quarter was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities analysts anticipate that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th were given a dividend of $1.72 per share. The ex-dividend date of this dividend was Tuesday, March 10th. This represents a $6.88 annualized dividend and a yield of 2.2%. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is currently 27.39%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.